Record $282M Revenue Underscores Growth, but Margin Questions Linger

What happened

Kewaunee Scientific reported record fiscal 2026 revenue of $282 million at its annual meeting, up from $240.5 million in fiscal 2025, representing roughly 17% growth driven by backlog conversion and Nu Aire contributions. Management outlined plans to continue investing in product development, manufacturing capacity, international expansion, and potential acquisitions to support fiscal 2027 growth. However, the announcement did not provide updated profitability figures, and prior quarters showed revenue growth outpacing earnings due to elevated operating and interest expenses tied to the Nu Aire integration. The stock has declined about 33% over the twelve months ending January 2026, reflecting market skepticism about earnings quality despite strong top-line momentum. The annual meeting commentary confirms strategic growth priorities but does not address the key question of whether EBITDA is expanding in line with sales.

Implication

The revenue milestone supports the base case that high-teens growth is achievable through backlog conversion, but the absence of margin and EBITDA detail means the market may not re-rate the stock until profitability improves. Planned investments, while strategically sound, are likely to keep operating expenses elevated in fiscal 2027, potentially pressuring near-term earnings unless revenue growth accelerates or cost discipline improves. If upcoming quarterly reports show EBITDA exceeding fiscal 2025 levels and lower interest expense after refinancing, the case for a higher valuation multiple strengthens. Conversely, if investments lead to another year of margin compression, the stock could remain rangebound or decline further. Given the current discounted valuation at approximately 9.5x trailing EPS and 5x EV/EBITDA, the risk-reward remains asymmetric to the upside, but patience is required until margin clarity emerges.

Thesis delta

The record revenue reinforces the growth leg of the thesis but does not change the central debate about margins and earnings quality. The announcement of further investments slightly raises the risk of continued near-term profitability pressure, yet it also signals management's confidence in long-term demand. The thesis remains a 'potential buy' with conviction of 4, but the investment case now hinges more on upcoming quarterly reports to show improved EBITDA and interest expense reductions.